Bryn Mawr Capital Management LLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 11.1% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 114,716 shares of the company's stock after selling 14,322 shares during the quarter. Johnson & Johnson makes up approximately 1.1% of Bryn Mawr Capital Management LLC's holdings, making the stock its 16th biggest position. Bryn Mawr Capital Management LLC's holdings in Johnson & Johnson were worth $19,025,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. WealthTrak Capital Management LLC bought a new stake in Johnson & Johnson during the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $29,000. Conquis Financial LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at about $33,000. Bernard Wealth Management Corp. acquired a new position in Johnson & Johnson during the fourth quarter worth approximately $36,000. Finally, Highline Wealth Partners LLC raised its stake in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares during the period. Institutional investors own 69.55% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on the company. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price target for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Wall Street Zen raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Raymond James Financial reduced their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a report on Monday, April 14th. UBS Group reissued a "buy" rating and issued a $190.00 price target (up from $180.00) on shares of Johnson & Johnson in a report on Thursday. Finally, Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $174.11.
Check Out Our Latest Stock Analysis on Johnson & Johnson
Johnson & Johnson Price Performance
JNJ stock traded down $1.05 during mid-day trading on Thursday, hitting $163.73. The stock had a trading volume of 6,977,621 shares, compared to its average volume of 8,146,461. The firm has a fifty day simple moving average of $153.95 and a 200 day simple moving average of $154.71. The firm has a market capitalization of $393.95 billion, a P/E ratio of 18.20, a P/E/G ratio of 2.12 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the business posted $2.82 EPS. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. As a group, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.18%. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.
Johnson & Johnson Company Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
